Quanterix (QTRX) Reports Q2 Revenues of $25.4M

Quanterix (NASDAQ: QTRX) reported Q2 revenue of $25.4 million versus the consensus estimate of $23.38 million.

“The past quarter has proven to be a pivotal time for our company as we continue to make immense strides with our strategic expansion in the diagnostics space,” said Kevin Hrusovsky, Chairman and Chief Executive Officer, Quanterix. “With drug advances taking place for neurodegenerative diseases, there is a heightened focus to diagnose and detect cognitive conditions like Alzheimer’s Disease as early as possible and then to monitor disease progression in the patient once a drug agent is deployed. We are a leader in this area and improving outcomes and helping advance methodologies to enhance coverage with evidence for payers will change the way disease is studied, drugs are approved and ultimately how care is delivered economically and effectively.”

For earnings history and earnings-related data on Quanterix (QTRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• AMC Entertainment prices $200M stock offering to redeem senior notes
• Sunstone Hotel Investors to sell Hyatt Regency San Francisco for $279M